Zepbound, or tirzepatide, was associated with nearly 50% more weight loss than Wegovy, or semaglutide, in a 72-week study published in The New England Journal of Medicine. Participants on Zepbound lost, on average, 50 pounds, compared with 33 pounds for those taking Wegovy. Both drugs, which mimic hormones that regulate appetite, had similar side effects, primarily mild gastrointestinal issues.
Full Story: The Associated Press (5/11)